Dr. Mitchell Brin serves as Senior Vice President, R&D and Chief Scientific Officer, BOTOX® and Neurotoxins at AbbVie. In this role, he provides cross-functional strategic leadership of BOTOX® and neurotoxins across the continuum of R&D through commercialization and manufacturing. He also leads the Neurotoxin Franchise Strategy Team (NFST), which supports strategic integration and alignment across this continuum. He is a Distinguished Research Fellow, AbbVie Community of Science.
In 2001, Dr. Brin joined Allergan as Therapeutic Area Head for BOTOX® and Neurology and has been personally responsible for leading or contributing to all global and regional development and licensure of BOTOX®. Dr. Brin is also a Clinical Professor of Neurology at the University of California Irvine and volunteers evaluating and treating patients. He serves on UCI’s School of Biology Dean’s Leadership Council, and UCI Applied Innovation, and is a Fellow of the American Academy of Neurology, American Neurological Association, and American Headache Society.
Prior to joining AbbVie, he graduated with a B.A. in biology from the University of Pennsylvania and received his M.D. from Columbia College of Physicians and Surgeons. He completed a neurology residency and movement disorders fellowship at Columbia University Neurological Institute. At Columbia, he explored neurological and aesthetic patient benefits of local injections of botulinum toxin, and coordinated the Dystonia Clinical Research Center. In 1994, he continued research and clinical activities at Mount Sinai School of Medicine, and subsequently became the Bachmann-Strauss Endowed Professor in Neurology.